Chimerix

2007

Chimerix Initiates A Multi-Dose Clinical Trial Of The Company’s Lead Compound, CMX001, For The Treatment For Smallpox Infection    

RESEARCH TRIANGLE PARK, NC, December 11, 2007 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has initiated a multi-dose trial with its lead drug candidate, CMX001, an oral treatment for… > Read More

Chimerix Raises $23.1 Million to Advance Antiviral Drug Pipeline    

RESEARCH TRIANGLE PARK, NC, February 23, 2007 - Chimerix Inc., a biotechnology company developing orally available antiviral therapeutics, today announced a $23.1 million private placement of its Series D preferred stock. New investor, Canaan Partners, led the round, and Seth Rudnick… > Read More

Merial To Screen Chimerix' Chemical Library For Animal Health Drug Leads    

DULUTH, GA, and RESEARCH TRIANGLE PARK, NC, January 29, 2007 - Merial Limited and Chimerix, Inc. announced today that they have signed an agreement under which Merial will screen a Chimerix chemical library for animal health drug leads. Under the terms of this agreement,… > Read More